@



@

@

@

@

•½¬‚Q‚O”N“xŠˆ“®Ž‘‹àŠñ•tŠé‹Æ ‹y‚Ñ Šñ•t‹¦—ÍŽÒ

i•½¬‚Q‚O”N‚P‚QŒŽŒ»Ýj

œ@ƒAƒXƒgƒ‰ƒ[ƒlƒJДޮ‰ïŽÐ

@

œ@Îì@”ü’qŽq

œ@ƒG[ƒUƒCДޮ‰ïŽÐ

œ@ˆÇ—Ñ»–òДޮ‰ïŽÐ

œ@¬–ì–ò•iH‹ÆŠ”Ž®‰ïŽÐ

œ@Glaxo-SmithKlineДޮ‰ïŽÐ

œ@Дޮ‰ïŽÐ‹¦˜aŠé‰æ

œ@Дޮ‰ïŽÐƒ|[ƒ‰ƒtƒ@[ƒ}

œ@’è‰i@‹±–¾

œ@ƒTƒmƒtƒBEƒAƒ”ƒFƒ“ƒeƒBƒXДޮ‰ïŽÐ

œ@‘å“ú–{Z—F»–òДޮ‰ïŽÐ

œ@äÝ—L»–òДޮ‰ïŽÐ

œ@“c•ÓŽO•H»–òДޮ‰ïŽÐ

œ@‹¦˜a”­yƒLƒŠƒ“Дޮ‰ïŽÐ


•½¬‚P‚X”N“xŠˆ“®Ž‘‹àŠñ•tŠé‹Æ

œ@ƒAƒXƒgƒ‰ƒ[ƒlƒJДޮ‰ïŽÐ

@

œ@Glaxo-SmithKlineДޮ‰ïŽÐ

œ@‘å’Ë»–òДޮ‰ïŽÐ

œ@¬–ì–ò•iH‹ÆŠ”Ž®‰ïŽÐ

œ@Дޮ‰ïŽÐ‹¦˜aŠé‰æ

œ@ƒVƒFƒŠƒ“ƒOEƒvƒ‰ƒEДޮ‰ïŽÐ

œ@ƒLƒbƒZƒC–ò•iH‹ÆŠ”Ž®‰ïŽÐ

œ@ˆÇ—Ñ»–òДޮ‰ïŽÐ

œ@‹¦˜a”­yH‹ÆŠ”Ž®‰ïŽÐ

œ@’élƒtƒ@[ƒ}Дޮ‰ïŽÐ

œ@‘å“ú–{Z—F»–òДޮ‰ïŽÐ

œ@ƒmƒoƒ‹ƒeƒBƒXƒtƒ@[ƒ}Дޮ‰ïŽÐ@


•½¬‚P‚W”N“xŠˆ“®Ž‘‹àŠñ•tŠé‹Æ

œ@ƒAƒXƒgƒ‰ƒ[ƒlƒJДޮ‰ïŽÐ

@

œ@ƒmƒoƒ‹ƒeƒBƒXƒtƒ@[ƒ}Дޮ‰ïŽÐ@

œ@ƒG[ƒUƒCДޮ‰ïŽÐ

œ@¬–ì–ò•iH‹ÆŠ”Ž®‰ïŽÐ

œ@Дޮ‰ïŽÐ‹¦˜aŠé‰æ

œ@ƒLƒbƒZƒC–ò•iH‹ÆŠ”Ž®‰ïŽÐ

œ@Glaxo-SmithKlineДޮ‰ïŽÐ

œ@ˆÇ—Ñ»–òДޮ‰ïŽÐ

œ@‹¦˜a”­yH‹ÆŠ”Ž®‰ïŽÐ

œ@ƒVƒFƒŠƒ“ƒOEƒvƒ‰ƒEiŠ”j

œ@‘峕xŽRˆã–ò•iДޮ‰ïŽÐ

œ@‘å“ú–{Z—F»–òДޮ‰ïŽÐ

œ@’élƒtƒ@[ƒ}Дޮ‰ïŽÐ

œ@–¾Ž¡»‰ÙДޮ‰ïŽÐ